Author

A. Hamai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

C. Desterke· 2 shared Y. Chang· 2 shared A. Jalil· 1 shared C. Ansaldi· 1 shared C. Drouot· 1 shared C. Duruel· 1 shared C. Guerrera· 1 shared C. Serdjebi· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Desterke

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

mTOR Inhibition Suppresses Salinomycin-Induced Ferroptosis in Breast Cancer Stem Cells by Ironing Out Mitochondrial Dysfunctions

E. Cosialls, E. Pacreau, S. Ceccacci, R. Elhage, C. Duruel, C. Desterke, K. Roger, C. Guerrera, R. Ducloux, S. Souquere, G. Pierron, I. Nemazanyy, M. Kelly, E. Dalmas, Y. Chang, , A. Hamai

The paper shows that mTOR inhibition reduces Salinomycin-induced ferroptosis in breast cancer stem cells by modulating iron flux and mitochondrial function.

bioRxiv · May 2, 2023Cancer Biology

The HP1γ epigenetic silencer dampens IFN-γ response at the gut epithelial barrier

Y. Chang, J. Mata-Garrido, C. desterke, E. Batsche, A. Hamai, S. Youssouf, D. Skurnik, A. Jalil, J.-C. Beche, E. Piaggio, L. Arbibe, Y. C. Marchand

This study identifies HP1γ as an epigenetic repressor of IFN-γ responsive genes at the gut epithelial barrier, showing its role in dampening immune responses.

bioRxiv · Dec 27, 2022 · PreprintImmunology

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

S. BRUN, E. Raymond, F. Bassissi, Z. M. Jilkova, S. Mezouar, M. Rachid, M. Novello, J. Tracz, A. Hamai, G. Lalmanach, L. Vanderlynden, E. Bestion, R. Legouffe, J. Stauber, T. Schubert, , P. Halfon

This paper evaluates GNS561, a PPT1 inhibitor, showing its efficacy against HCC by modulating lysosomal functions and inducing cell death in vitro and in vivo.

bioRxiv · Sep 30, 2020Cancer Biology